IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A monoclonal antibody, which exhibits a selectivity in cross reaction with N-carbamyl-β-alanine of 10% or less, when the selectivity in cross reaction with uracil or thymine is 90% or more.

Claim 2 (Previously Presented): The monoclonal antibody of claim 1, which exhibits low reactivity with pseudouridine, dihydrouracil, and dihydrothymine.

Claim 3 (Canceled).

Claim 4 (Previously Presented): The monoclonal antibody of claim 1, which exhibits a selectivity in cross reaction with N-carbamyl-β-alanine of 10% or less; a selectivity in cross reaction with pseudouridine of 33% or less; a selectivity in cross reaction with dihydrouracil of 8% or less; and a selectivity in cross reaction with dihydrothymine of 23% or less; when the selectivity in cross reaction with uracil or thymine is 90% or more.

Claim 5 (Currently Amended): The monoclonal antibody ~~as described~~ of claim 1, which is produced from a hybridoma which is formed from a myeloma cell and an antibody-producing cell derived from an animal to which 5-halogeno-1carboxymethyluracil has been administered.

Claim 6 (Previously Presented): The monoclonal antibody as described in claim 5, wherein the hybridoma is FERM BP-6870.

Claim 7 (Previously Presented): A hybridoma producing the monoclonal antibody of claim 1.

Claim 8 (Currently Amended): A method for immunochemically assaying uracil and thymine comprising contacting a sample possibly containing uracil and thymine with the monoclonal antibody of claim 1; and

detecting ~~the formation of an~~ a formed antibody-antigen complex , wherein the presence of the antibody-antigen complex is indicative of the presence of uracil and thymine in the sample.

Claim 9 (Previously Presented): A composition, comprising the monoclonal antibody of claim 1; and a carrier.

Claim 10 (Currently Amended): A method for diagnosing DPD deficiency in an individual, comprising, assaying uracil and thymine according to the method of claim 8, wherein the sample is obtained from the individual and wherein ~~the presence~~ an increase of uracil and thymine in the sample relative to a sample obtained from an individual that is not DPD deficient is diagnostic for DPD deficiency in the individual.

Claim 11 (Canceled).

Claim 12 (New): A hybridoma producing the monoclonal antibody of claim 4.

Claim 13 (Currently Amended): A method for immunochemically assaying uracil and thymine comprising contacting a sample possibly containing uracil and thymine with the monoclonal antibody of claim 4; and

detecting ~~the formation of an~~ a formed antibody-antigen complex, wherein ~~the presence of the~~ a detected antibody-antigen complex is indicative of the presence of uracil and thymine in the sample.

Claim 14 (Previously Presented): A composition, comprising the monoclonal antibody of claim 4; and a carrier.

Claim 15 (Currently Amended): A method for diagnosing DPD deficiency in an individual, comprising, assaying uracil and thymine according to the method of claim 13, wherein the sample is obtained from the individual and wherein ~~the presence~~ an increase of uracil and thymine in the sample relative to a sample obtained from an individual that is not DPD deficient is diagnostic for DPD deficiency in the individual.

Claim 16 (Previously Presented): A hybridoma producing the monoclonal antibody of claim 6.

Claim 17 (Currently Amended): A method for immunochemically assaying uracil and thymine comprising contacting a sample possibly containing uracil and thymine with the monoclonal antibody of claim 6; and

detecting ~~the formation of an~~ a formed antibody-antigen complex, wherein ~~the presence of the~~ a detected antibody-antigen complex is indicative of the presence of uracil and thymine in the sample.

Claim 18 (Previously Presented): A composition, comprising the monoclonal antibody of claim 6; and a carrier.

Claim 19 (Previously Presented): A method for diagnosing DPD deficiency in an individual, comprising, assaying uracil and thymine according to the method of claim 17, wherein the sample is obtained from the individual and wherein ~~the presence~~ an increase of uracil and thymine in the sample relative to a sample obtained from an individual that is not DPD deficient is diagnostic for DPD deficiency in the individual.